Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06120842 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
A Phase 1 study of Glaucoma and Cataract, sponsored by SpyGlass Pharma.
- Active
- Registry status
- Phase 1
- Development phase
- 201
- Enrollment target
- 1
- Study location
NCT06120842: Active Phase 1 study of Glaucoma and Cataract, sponsored by SpyGlass Pharma.
NCT06120842 is a Phase 1 study of Glaucoma and Cataract that is active but no longer recruiting, run by SpyGlass Pharma. The registered enrollment target is 201 participants, below the 908-participant average among 92 other Glaucoma trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06120842, a Phase 1 study of Glaucoma and Cataract, is active but no longer recruiting, sponsored by SpyGlass Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 201 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial is a randomized study to evaluate and compare two doses of the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.
Primary Outcome
Time matched mean IOP reduction from Baseline (mmHg) in the study eyes at all the individual IOP timepoints
Conditions Studied
Interventions
- DEVICE SpyGlass IOL
- DRUG Timolol Maleate Ophthalmic Solution, 0.5%
- DRUG Bimatoprost Implant System (High Dose)
- DRUG Bimatoprost Implant System (Low Dose)
- DEVICE Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL
Study Locations (1)
Arizona
- Arizona Advanced Eye Research Institute - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2023-10-13 |
| Est. Completion | 2027-11 |
| Phase | Phase 1 |
What the registry record for NCT06120842 still lists
NCT06120842 is an interventional study that assigns participants to a tested intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, below the 908-participant average among 92 other Glaucoma trials with a reported enrollment target (78% lower).
The record links to 3 conditions, with Glaucoma appearing as the primary indexed condition, and to 5 interventions - of which SpyGlass IOL is the first listed.
NCT06120842 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06120842 about?
NCT06120842 is a clinical study titled "Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution". This trial is a randomized study to evaluate and compare two doses of the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.
What is the current status of trial NCT06120842?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 201 participants. The study started on 2023-10-13. Estimated completion is 2027-11.
What conditions does trial NCT06120842 study?
This clinical trial studies the following conditions: Glaucoma, Cataract, Ocular Hypertension.
What interventions are being tested in trial NCT06120842?
The interventions under investigation include: SpyGlass IOL (DEVICE), Timolol Maleate Ophthalmic Solution, 0.5% (DRUG), Bimatoprost Implant System (High Dose) (DRUG), Bimatoprost Implant System (Low Dose) (DRUG), Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL (DEVICE).
Who is sponsoring clinical trial NCT06120842?
This trial is sponsored by SpyGlass Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06120842 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06120842's enrollment target sits among peer trials
201 26th of 92 higher than 67 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
-
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
ACTIVE NOT RECRUITING · Phase 1
-
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
COMPLETED · Phase 1
-
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
COMPLETED · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
COMPLETED · Phase 1
-
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04422652 · 201 participants · Phase 2
Combination of Novel Therapies for CKD Comorbid Depression
- NCT05327114 · 201 participants · Phase 2
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT06099769 · 201 participants · Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- NCT06274528 · 201 participants · Phase 2
DORA and LP in Alzheimer's Disease Biomarkers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI